|
Post by techorfund on Feb 2, 2017 12:32:20 GMT -5
Read this with a sarcastic tone. Since we are R/S on "strength", I would expect massive amounts of stock buys by Matt, Mike and the board members after the R/S. Yeah right!
Non-sarcastic tone. Not if, but when the R/S 10:1 passes, the breakeven point for me is then $50p/s for my cash account and $75 for my 457 account. Oh well, I'll just let it play out.
|
|
|
Post by nemzter on Feb 2, 2017 12:36:38 GMT -5
I would sell now before the RS gets approved... stock isn't going any higher than where it is now.
Would you like to have an 10:1 RS at .20c/share?
Shorts will be driving this down further before the RS IMO
|
|
|
Post by afleischner on Feb 2, 2017 12:40:08 GMT -5
reverse split is a death knell. I will vote against
|
|
|
Post by esstan2001 on Feb 2, 2017 12:52:00 GMT -5
reverse split is a death knell. I will vote against Unfortunately, not having the R/S option means NASDAQ delisting if unable to perk up the $ over a buck for 10 consecutive days (some deal with upfront is the only way I see this happening w/in the next 3 mo.) Not being on the NAS Natn'l Mkt reduces the options to obtain financing... increasing the odds of bankruptcy filing before they get a chance to demonstrate a reasonable script trajectory or secure some more deals. There seems to be little choice but to vote in favor of the option and hope they really execute and get lucky.
|
|
|
Post by promann on Feb 2, 2017 13:05:07 GMT -5
I'm still in shock and pretty much speechless.. I'm not selling been here for 5 years it's way to late to sell. I still believe Afrezza will be a hit just hang on fellow longs it can't get much worse we are still way under valued. The shorts want our shares don't let them off the hook. I wonder how many were smart enough to cover today taking longs shares?
|
|
|
Post by majorwood on Feb 2, 2017 14:00:22 GMT -5
I'm long MNKD as I have been since pre FDA approval. Although much has transpired in the last few years I still believe in the product and anticipate sales will increase soon. I'll be looking for opportunities to accumulate more and someday in the next few years I'll be extremely EXTREMELY rich. Keep spreading the word my friends and lets not give up on this co and it's life changing Afrezza.
|
|
|
Post by slugworth008 on Feb 2, 2017 14:49:30 GMT -5
I am curious who will still stay long after today's event? I will. My argument is that I have stayed long for so long, why quit now. I'm in - WTF - I'm way underwater anyway and Afrezza IS that good. Of course I'd take a 5$ buyout right about now too.
|
|
|
Post by slugworth008 on Feb 2, 2017 14:51:20 GMT -5
I'm long MNKD as I have been since pre FDA approval. Although much has transpired in the last few years I still believe in the product and anticipate sales will increase soon. I'll be looking for opportunities to accumulate more and someday in the next few years I'll be extremely EXTREMELY rich. Keep spreading the word my friends and lets not give up on this co and it's life changing Afrezza. Mike's comment that 9 out of ten people haven't heard of Afrezza IS, I repeat IS, the problem. DTC was needed long ago IMO.
|
|
|
Post by swanybuaya on Feb 2, 2017 15:20:52 GMT -5
I'm long MNKD as I have been since pre FDA approval. Although much has transpired in the last few years I still believe in the product and anticipate sales will increase soon. I'll be looking for opportunities to accumulate more and someday in the next few years I'll be extremely EXTREMELY rich. Keep spreading the word my friends and lets not give up on this co and it's life changing Afrezza. Mike's comment that 9 out of ten people haven't heard of Afrezza IS, I repeat IS, the problem. DTC was needed long ago IMO. Agreed 1000%.
|
|
|
Post by nylefty on Feb 2, 2017 15:53:13 GMT -5
Mike's comment that 9 out of ten people haven't heard of Afrezza IS, I repeat IS, the problem. DTC was needed long ago IMO. Agreed 1000%. But what about the argument that money for DTC is wasted if docs won't prescribe or (because of label restrictions) don't know how Afrezza should be taken? Poor renewal numbers is a huge problem, mostly because patients don't know how to use Afrezza -- and DTC won't fix that. Let's hope the new sales force can somehow educate more docs without running afoul of the FDA.
|
|
|
Post by wgreystone on Feb 2, 2017 16:13:19 GMT -5
RS does not change the fundamental. It may actually help open up the long base. Most 401K do not allow buying stocks under $1. Many long funds do not buy stocks under $5.
|
|
|
Post by falconquest on Feb 2, 2017 17:48:32 GMT -5
RS does not change the fundamental. It may actually help open up the long base. Most 401K do not allow buying stocks under $1. Many long funds do not buy stocks under $5. Yep, got that going for us!
|
|
|
Post by slugworth008 on Feb 2, 2017 21:49:37 GMT -5
But what about the argument that money for DTC is wasted if docs won't prescribe or (because of label restrictions) don't know how Afrezza should be taken? Poor renewal numbers is a huge problem, mostly because patients don't know how to use Afrezza -- and DTC won't fix that. Let's hope the new sales force can somehow educate more docs without running afoul of the FDA. Should have been a two pronged approach NY Lefty. They totally dropped the ball on this. IMO
|
|
|
Post by swanybuaya on Feb 2, 2017 22:26:30 GMT -5
But what about the argument that money for DTC is wasted if docs won't prescribe or (because of label restrictions) don't know how Afrezza should be taken? Poor renewal numbers is a huge problem, mostly because patients don't know how to use Afrezza -- and DTC won't fix that. Let's hope the new sales force can somehow educate more docs without running afoul of the FDA. When Mike was talking about educating the doctors the next breath he said it helps when patients go in and ask about the product. The only way that is accomplished, on a large scale, is DTC. What's disturbing is the confusion on how to use the product. How many years has this been in development? Product usage should have been ironed-out way before the initial launch.
|
|
|
Post by saxcmann on Feb 2, 2017 22:37:27 GMT -5
But what about the argument that money for DTC is wasted if docs won't prescribe or (because of label restrictions) don't know how Afrezza should be taken? Poor renewal numbers is a huge problem, mostly because patients don't know how to use Afrezza -- and DTC won't fix that. Let's hope the new sales force can somehow educate more docs without running afoul of the FDA. Should have been a two pronged approach NY Lefty. They totally dropped the ball on this. IMO Its more complicated than that. That's the problem. Its more like a 5 prong approach. That's why it take so much time and money to be successful. All 5 pronges must improve to get scripts up, imo. My 5 prong approach... 1. DTC Advertising for awareness 2. *Educate Endos(type 1) 3. *Educate PCPs(type 2) 4. Improve Label/Clinical Data 5. Increase Insurance Coverage *Educate doctors to understand roadblocks... 1. Spirometry test (portable, cheap) 2. Dosing/Titration (samples, sizes, etc) 3. Mannkind Cares (Insurance hurdles) 4. PK/PD Profile (differences from RAAs)
|
|